Zenara Pharma Generic Eliglustat Tartrate Receives Approval in the U.S.A
Dr. Reddy's Generic Eliglustat Tartrate Receives Approval in the U.S.
Aizant's Generic Eliglustat Tartrate Receives Approval in the US
Cerdelga (eliglustat) : Genzyme vs. Apotex
FDA Confirms Paragraph IV Patent Challenge of Cerdelga (Eliglustat) Tablets
List of Paragraph IV Patent Certifications Oct 8, 2018
The latest batch of decisions by the Scottish Medicines Consortium has given patients with certain forms of breast cancer, Gaucher disease and erectile dysfunction new treatment options on the NHS.
Sanofi’s Cerdelga can now be funded on the NHS in England and Wales to treat type 1 Gaucher disease, after cost regulators issued final guidance backing ‘routine’ use of the therapy.
England’s NHS will routinely fund Sanofi/Genzyme’s Cerdelga (eliglustat) for the rare condition Gaucher disease after a recommendation from NICE.
The National Institute of Health and Care Excellence Wednesday issued a Final Evaluation Determination (PDF) on the med that backs it for long-term treatment in adults. But as usual, there’s a catch: The agency only recommends the drug when Sanofi provides it with an undisclosed, previously agreed-upon discount, or “patient access scheme.”